Business
Add as a preferred source on GoogleKimberly-Clark expected closing in the fourth quarter of 2026, subject to customary conditions.
Kimberly-Clark’s filing links Kenvue’s planned NYSE exit to the acquisition’s completion; the buyer said Sept. 28 that it expected a fourth-quarter 2026 close, subject to customary conditions.
Under the merger agreement, each eligible Kenvue share would convert into $3.50 in cash and 0.14625 Kimberly-Clark shares if the deal closes.
Atkore asked the New York Stock Exchange to delist its shares, while Prysmian expects to fully consolidate the business from November 2026.
The nonbinding approach was a proposal for a voluntary public offer covering all Evonik shares.
AstraZeneca spent more than $4 billion on deals this year to access new technologies, finance chief Aradhana Sarin said. She said smaller acquisitions had delivered the company's greatest success.
